SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes

Tejas Patel

doi:10.7326/J23-0002

SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes

Ann Intern Med. 2023 Mar;176(3):JC27. doi: 10.7326/J23-0002. Epub 2023 Mar 7.

Author

Tejas Patel¹

Affiliation

¹ Saint Francis Hospital, Catholic Health of Long Island, Roslyn, New York, USA (T.P.).

PMID: 36877973
DOI: 10.7326/J23-0002

Abstract

Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788-801. 36351458.

Publication types

Meta-Analysis
Comment

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Heart
Humans
Hypoglycemic Agents / adverse effects
Kidney
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents